“…However, there are considerable differencies regarding assessment concepts, data requirements, their analysis and interpretation (e.g. EFSA, 2010a, Graef et al, 2010, Gressel, 2010, Herman, 2010, Raybould, 2010, Schubert, 2010, Hilbeck et al, 2011. Little attention is given to cost-benefit assessments and the EU regulatory approach is specifically focused on risks rather than benefits of GMO (EFSA, 2008d, Miller and Bradford, 2010, Tabashnik, 2010, which is probably one of the reasons why there is an asynchronus authorization of GM plants worldwide.…”